Page 68 - Clinical Development News Today

Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.

Novotech CRO opens the ChinaTrials 15 conference in Shanghai, China on accelerating drug development....

Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3 Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of...

Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023

A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.

Israeli biopharma marketplace, 9Exchange, has partnered with PhaseV a causal machine learning (ML) company, it was announced yesterday (November 6).

People with Alcohol Use Disorder (AUD) could benefit from taking a daily tablet that could see their intake reduced by half in just three months.

PASADENA, Calif., November 07, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris® (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi® (U.S.)/Minjuvi® (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada’s largest defined be...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Good morning. My name is Ashley, and I’ll be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quater 2023 Financial Results Conference Call. All participant lines have been placed on mute to […]

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, including a...